PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
The user is using a hair loss treatment regimen that includes double the recommended dose of Minoxidil foam once nightly, a mix of RU58841 and stemoxydine after the Minoxidil dries, ketoconazole every other day, and weekly microneedling with alternating depths. They are also considering starting finasteride soon.
The user is using 5% topical minoxidil twice daily and 1.25 mg oral finasteride for hair thinning at the temples. They are considering switching to once-daily minoxidil due to scalp flakiness and future time constraints.
Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.
User experienced scalp itching and hair loss, but found relief with oral minoxidil. Others suggest "DHT itch" as a possible cause and recommend finasteride and ketoconazole to address it.
A 22-year-old is experiencing diffuse hair thinning all over the head, losing about 300 long hairs daily, despite having good genetics and vitamin levels. They are seeking advice on whether this pattern is normal and considering consulting a dermatologist.
The user added topical minoxidil to their finasteride regimen, resulting in healthier hair and some regrowth, especially after quitting nicotine. They experienced minimal shedding and noted improvements in hairline density, finding the treatment mostly preventative.
The user experienced hair regrowth over a year using minoxidil and inconsistent finasteride, along with a diet including natural DHT-blocking foods. They are pleased with the progress but aim for more consistency.
A user named "tresslessinseattle" receiving a mysterious package of Eucapil hair loss treatment, which they are considering in combination with Minoxidil and Finasteride treatments to boost the regrowth they have been seeing.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.